Tag: R/R FL treatment

Home / R/R FL treatment

Categories

Zanubrutinib is approved by the USFDA for relapsed or refractory follicular lymphoma

March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refra...
r-r-fl-treatment

Scan the code